Home » Stocks » Aeglea Biotherapeutics

Aeglea Biotherapeutics, Inc. (AGLE)

Stock Price: $6.85 USD -0.12 (-1.72%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 305.51M
Revenue (ttm) n/a
Net Income (ttm) -79.82M
Shares Out 44.60M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $6.85
Previous Close $6.97
Change ($) -0.12
Change (%) -1.72%
Day's Open 6.96
Day's Range 6.65 - 7.01
Day's Volume 240,263
52-Week Range 3.50 - 11.38

More Stats

Market Cap 305.51M
Enterprise Value 260.12M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.60M
Float 33.01M
EPS (basic) -2.43
EPS (diluted) -2.42
FCF / Share -2.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.14M
Short Ratio 2.22
Short % of Float 2.36%
Beta 2.07
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.26
Revenue n/a
Operating Income -81.70M
Net Income -79.82M
Free Cash Flow -74.34M
Net Cash 45.38M
Net Cash / Share 1.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -52.83%
ROE -100.34%
ROIC -136.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$15.74*
(129.78% upside)
Low
8.89
Current: $6.85
High
26.00
Target: 15.74
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue-3.895.214.636.09-
Revenue Growth--25.3%12.47%-23.94%--
Gross Profit-3.895.214.636.09-
Operating Income-80.33-45.46-27.68-21.91-11.32-8.90
Net Income-78.25-44.35-27.24-21.70-11.30-10.35
Shares Outstanding31.9520.8215.139.790.600.17
Earnings Per Share-2.45-2.13-1.80-2.22-19.21-
Operating Cash Flow-65.69-32.19-24.62-18.84-10.98-7.34
Capital Expenditures-1.49-0.42-0.62-0.21-0.21-0.18
Free Cash Flow-67.18-32.62-25.23-19.05-11.19-7.52
Cash & Equivalents73.4574.5150.3063.5033.142.66
Total Debt5.06-----
Net Cash / Debt68.3974.5150.3063.5033.142.66
Assets83.1877.7456.0867.0638.652.93
Liabilities23.1010.315.744.102.551.06
Book Value60.0867.4350.3462.97-22.21-11.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aeglea Biotherapeutics, Inc.
Country United States
Employees 79
CEO Anthony G. Quinn

Stock Information

Ticker Symbol AGLE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGLE
IPO Date April 7, 2016

Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.